BiotechTube

talfirastide + Placebo

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ischemic Stroke

Conditions

Ischemic Stroke

Trial Timeline

Nov 26, 2023 → Sep 1, 2025

NCT ID
NCT06135103

About talfirastide + Placebo

talfirastide + Placebo is a phase 2 stage product being developed by Constant Therapeutics for Ischemic Stroke. The current trial status is unknown. This product is registered under clinical trial identifier NCT06135103. Target conditions include Ischemic Stroke.

What happened to similar drugs?

10 of 14 similar drugs in Ischemic Stroke were approved

Approved (10) Terminated (3) Active (4)
✅RegadenosonAstellas PharmaApproved
✅StatinShionogiApproved
✅RepathaAmgenApproved
✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved
✅celecoxib + ibuprofen + placeboPfizerApproved
✅Eplerenone + Placebo or sugar pillPfizerApproved
✅Enoxaparin sodiumSanofiApproved

Hype Score Breakdown

Clinical
12
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06135103Phase 2UNKNOWN

Competing Products

20 competing products in Ischemic Stroke

See all competitors
ProductCompanyStageHype Score
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
DS-1040b + AspirinDaiichi SankyoPhase 1
29
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
RegadenosonAstellas PharmaPhase 1
29
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
RegadenosonAstellas PharmaApproved
43
ASP2246Astellas PharmaPhase 1/2
39
Gadolinium + AdenosineAstellas PharmaPhase 2/3
38
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
fospropofol + propofolEisaiPhase 2
35
PDE5 InhibitorsEli LillyPre-clinical
26
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
42
Elezanumab + PlaceboAbbViePhase 2
35
Balovaptan + PlaceboRochePhase 2
27
RepathaAmgenApproved
35